Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Feb 20, 2019
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how living with glioma, a type of brain tumor, affects patients' quality of life over time. Gliomas are the most common type of brain tumor, and they can be classified into different grades based on their characteristics. Because gliomas are often not curable, it’s really important to understand how treatments impact patients' daily lives, beyond just how long they live or how the tumor responds to treatment. Researchers want to look at how patients feel physically, emotionally, and socially as they go through their care.
To participate in this study, you need to be at least 18 years old and have been diagnosed and treated for a glioma at UZ Leuven. The trial is currently recruiting participants, and it welcomes individuals of all genders. If you join, you can expect to share information about your health and well-being, helping researchers understand the overall impact of gliomas on life quality. This study aims to provide valuable insights that could improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • age ≥ 18 years
- • patients diagnosed and treated for a high- or low grade glioma
- • treatment in UZ Leuven
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Trial Officials
Steven De Vleeschouwer, MD Phd
Principal Investigator
UZ Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials